How much cash does Ionis Pharmaceuticals generate?

Ionis Pharmaceuticals (IONS) generated -$910.6M in operating cash flow over the trailing twelve months.

What is Ionis Pharmaceuticals's free cash flow?

After $60.6M of capital expenditures, Ionis Pharmaceuticals's free cash flow was -$1.3B over the trailing twelve months, down 133.2% year over year.

Where does Ionis Pharmaceuticals's cash flow data come from?

Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Ionis Pharmaceuticals IONS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$326.98M+14.3%	-$381.39M-48.8%	-$256.34M+4.4%	-$268.22M+41.4%	-$458.03M-0.9%
Depreciation and amortization	$11.08M+10.7%	$10.01M+11.3%	$8.99M-1.2%	$9.1M-2.2%	$9.3M-3.3%
Stock-based compensation	$147.43M+10.1%	$133.87M+5.7%	$126.7M-0.7%	$127.54M-0.8%	$128.58M-1.2%
Deferred income taxes	$103K+10,200%	$1K-100.0%	$3.79M+8,714%	-$44K-210%	$40K—
Amortization of debt issuance costs	$7.62M+10.2%	$6.91M+4.4%	$6.61M-0.4%	$6.64M-0.4%	$6.67M-0.4%
Change in inventories	$15.27M+4.6%	$14.6M-25.7%	$19.64M+12.2%	$17.51M+262%	$4.83M-9.6%
Change in accounts payable	——	——	——	——	-$10.04M-163%
Change in other assets	——	——	$141.19M+251%	$40.24M-20.3%	$50.5M+86.5%
Change in other liabilities	——	——	$73.35M—	——	——
Other working capital changes	$60.11M+6,010,587,819,196%	$0—	——	——	——
Change in deferred revenue	-$76.83M-10.2%	-$69.73M-7.4%	-$64.9M+20.6%	-$81.76M+33.9%	-$123.72M+21.1%
Change in income taxes payable/receivable	$2.79M+2.5%	$2.72M+2,494%	$105K+166%	-$158K—	——
Amortization of intangible assets	$965K-2.1%	$986K+161%	-$1.62M-155%	$2.94M-0.7%	$2.96M-2.4%
Net gains (losses) on investments	$34.97M+242%	$10.22M+48.9%	$6.86M+131%	-$22.17M-200%	-$7.39M—
Non-cash operating lease expense	$11.15M+8.8%	$10.25M+9.3%	$9.37M-8.7%	$10.26M+1.0%	$10.16M+1.2%
Net cash from operating activities	-$910.63M-239%	-$268.58M-8.7%	-$247.01M-7.1%	-$230.57M+54.1%	-$501.78M-0.2%
Capital expenditures	$60.63M+17.9%	$51.44M-7.6%	$55.65M-6.4%	$59.44M+11.4%	$53.36M+17.9%
Purchases of investments	$1.8B-6.2%	$1.92B+31.4%	$1.46B-21.1%	$1.85B+12.6%	$1.64B-11.2%
Proceeds from maturities/sales of investments	$1.96B+15.2%	$1.7B-2.0%	$1.73B+3.1%	$1.68B+1.1%	$1.66B-6.0%
Purchases of intangible assets	$6.48M+14.8%	$5.64M-17.3%	$6.82M—	——	——
Proceeds from sale of property, plant and equipment	——	——	——	——	——
Acquired in-process research and development	——	$915.62M+0.4%	$912.1M+0.4%	$908.57M+0.4%	$905.05M+0.4%
Net cash from investing activities	$88.59M+132%	-$277.78M—	——	——	——
Proceeds from issuance of common stock	$55.06M—	$0-100%	$27K-100.0%	$492.66M-0.3%	$493.96M-4.1%
Net cash from financing activities	$730.9M+8.1%	$675.84M+698%	$84.66M-83.1%	$499.49M-0.3%	$500.8M-4.1%
Effect of exchange rate changes on cash	——	——	——	$691K+847%	$73K+127%
Net increase (decrease) in cash	-$90.81M-170%	$130.18M+3,385%	$3.74M—	——	——
Interest paid	$10.78M0.0%	$10.78M+2.2%	$10.55M+0.4%	$10.51M-3.2%	$10.87M0.0%
Income taxes paid	——	——	——	——	-$6.03M-7.3%
Accretion (Amortization) of Discounts and Premiums, Investments	$22.82M-3.9%	$23.74M-13.7%	$27.51M-12.8%	$31.57M-11.3%	$35.58M-5.7%
Stock-based compensation	$147.43M+10.1%	$133.87M+5.7%	$126.7M-0.7%	$127.54M-0.8%	$128.58M-1.2%
Amortization expense related to capitalized debt issuance costs	$7.62M+10.2%	$6.91M+4.4%	$6.61M-0.4%	$6.64M-0.4%	$6.67M-0.4%
Amortization of capitalized software and acquired intangible assets	$2.52M+3.2%	$2.44M+7.9%	$2.26M+0.2%	$2.26M-1.0%	$2.28M-2.4%
Depreciation	$11.08M+10.7%	$10.01M+11.3%	$8.99M-1.2%	$9.1M-2.2%	$9.3M-3.3%
Gain (Loss) on Investments	$34.97M+242%	$10.22M+48.9%	$6.86M+131%	-$22.17M-200%	-$7.39M-156%
Income Tax Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Increase (Decrease) in Contract with Customer, Asset	——	——	——	——	——
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	——	$2.68M+81.0%	$1.48M+427%	$281K+131%	-$918K+56.6%
Current liabilities	——	——	$73.35M—	——	——
Increase (Decrease) in Other Employee-Related Liabilities	——	——	——	——	——
Increase (Decrease) in Other Operating Assets	——	——	$141.19M+251%	$40.24M-20.3%	$50.5M+86.5%
Debt conversion inducement expense	——	$16.34M+33.3%	$12.26M+50.0%	$8.17M+100%	$4.09M—
Operating lease right-of-use asset amortization	$11.15M+8.8%	$10.25M+9.3%	$9.37M-8.7%	$10.26M+1.0%	$10.16M+1.2%
Net realized gains (losses)	$33.87M+259%	$9.44M+37.5%	$6.87M—	——	——
Payments to Acquire Intangible Assets	$6.48M+14.8%	$5.64M-17.3%	$6.82M—	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$1.96B+15.2%	$1.7B-2.0%	$1.73B+3.1%	$1.68B+1.1%	$1.66B-6.0%
Proceeds from disposals of property, plant and equipment	——	——	——	——	——
Proceeds from exercises of stock options and other stock issuances	$247.67M+28.6%	$192.6M+126%	$85.19M+679%	$10.93M-10.7%	$12.24M-63.6%
Repayments Of Secured Debt	$177K+1.1%	$175K+6.7%	$164K-4.1%	$171K+0.6%	$170K+1.8%
Contract With Customer Liability Revenue Recognized	——	$78.4M-21.9%	$100.33M-17.9%	$122.25M-15.2%	$144.18M-13.2%
Cost of services	$17.43M+9.6%	$15.91M+35.0%	$11.78M+12.0%	$10.52M-0.1%	$10.53M-6.1%
Costs and Expenses	$1.41B+6.4%	$1.33B+6.5%	$1.25B+2.8%	$1.21B+1.8%	$1.19B+0.8%
Current Income Tax Expense (Benefit)	——	$1.79M+979%	-$203.25K+90.7%	-$2.19M+47.6%	-$4.18M+32.2%
U.S. state and local	——	$2.58M+49.7%	$1.72M+99.0%	$866K+9,522%	$9K+101%
Defined Contribution Plan, Cost	——	$10.6M+5.0%	$10.1M+5.2%	$9.6M+5.5%	$9.1M+5.8%
U.S. federal statutory tax	——	——	——	——	——
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate	——	——	——	——	——
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost	——	——	——	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	——	-$381.18M+5.0%	-$401.06M+4.7%	-$420.95M+4.5%	-$440.83M+4.3%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	$1.58M+17.4%	$1.35M+21.0%	$1.11M+26.6%	$877.75K+36.3%
Effective Income Tax Rate Reconciliation, Tax Credit, Amount	——	——	——	——	——
Interest expense	$18.31M+6.1%	$17.26M+3.8%	$16.63M+0.3%	$16.57M-2.2%	$16.95M-0.3%
Number of Operating Segments	1.8+75.0%	1—	——	——	——
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	$375K-49.7%	$745K+188%	$259K-62.5%	$691K+860%	$72K+126%
Revenues	——	——	——	——	——
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	——	$0-100%	$27.5K-50.0%	$55K-33.3%	$82.5K-25.0%
Increases based on tax positions related to the current period	——	$7.16M+14.0%	$6.28M+16.2%	$5.41M+19.4%	$4.53M+24.1%
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	——	$137K-93.1%	$2M-48.2%	$3.86M-32.5%	$5.72M-24.5%
Foreign income taxes, net of refunds	——	$46K—	——	——	——
Total state income taxes, net of refunds	——	-$648K—	——	——	——
Income Taxes Paid, Net	——	——	——	——	-$6.03M-7.3%
Free cash flow	——	——	——	——	-$555.15M-1.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Ionis Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Ionis Pharmaceuticals generate?: Ionis Pharmaceuticals (IONS) generated -$910.6M in operating cash flow over the trailing twelve months.
What is Ionis Pharmaceuticals's free cash flow?: After $60.6M of capital expenditures, Ionis Pharmaceuticals's free cash flow was -$1.3B over the trailing twelve months, down 133.2% year over year.
Where does Ionis Pharmaceuticals's cash flow data come from?: Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.